Free Trial
OTCMKTS:HYPMY

Hypermarcas 7/27/2023 Earnings Report

Hypermarcas logo
$5.02 -0.01 (-0.14%)
As of 07/7/2025 03:58 PM Eastern

Hypermarcas EPS Results

Actual EPS
$0.16
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Hypermarcas Revenue Results

Actual Revenue
$450.80 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Hypermarcas Announcement Details

Quarter
Time
N/A
Conference Call Date
N/A
Conference Call Time
N/A

Upcoming Earnings

Hypermarcas' next earnings date is estimated for Wednesday, July 23, 2025, based on past reporting schedules.

Conference Call Resources

Hypermarcas Earnings Headlines

$100 Trillion “AI Metal” Found in American Ghost Town
Jeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could be the biggest technology story of this decade. In short, he believes what he's holding in his hand is the key to the $100 trillion AI boom… And only one company here in the U.S. can mine this obscure metal.
Hypera S.A. Reports 2024 Financial Performance
See More Hypermarcas Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Hypermarcas? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Hypermarcas and other key companies, straight to your email.

About Hypermarcas

Hypermarcas (OTCMKTS:HYPMY) S.A. is a Brazil-based consumer goods and pharmaceutical company principally engaged in the research, development, manufacturing and marketing of prescription medications, generic drugs, over-the-counter (OTC) products, health and hygiene items, vitamins, nutritional supplements and sports nutrition. Headquartered in São Paulo, the company operates multiple manufacturing sites and a dedicated R&D center in the state of São Paulo, supporting its efforts to expand and adapt product offerings to the Brazilian market.

The company’s pharmaceutical portfolio encompasses a broad range of therapeutic areas, including cardiovascular, central nervous system, dermatology, gastrointestinal and women’s health. Its generics division provides cost-effective alternatives to leading brand-name drugs, while its OTC segment features well-known brands in pain relief, cold and flu remedies, and digestive aids. Hypermarcas also maintains a consumer goods arm offering personal care and hygiene products, leveraging both domestic distribution channels and a growing presence in select Latin American markets.

Founded in the early 2000s by members of the Staub family, Hypermarcas pursued an acquisitive growth strategy that included the integration of several regional pharmaceutical manufacturers and consumer-goods firms. Key transactions over the past decade have strengthened its generics platform and enhanced its sports nutrition capabilities. The company’s expansion has been supported by modernization of production facilities and the implementation of robust regulatory and quality-control systems, in line with Brazil’s health authorities.

Governance at Hypermarcas is overseen by a board comprised of founding-family members and independent directors with deep industry experience. The executive leadership team, led by a chief executive officer and supported by senior vice presidents across R&D, manufacturing, commercial and finance functions, emphasizes innovation, operational efficiency and strategic partnerships. Through direct sales forces, national distributors and e-commerce channels, Hypermarcas seeks to maintain market leadership in Brazil’s competitive pharmaceutical and consumer goods sectors.

View Hypermarcas Profile

More Earnings Resources from MarketBeat